VK2735 is the obesity drug that put a smaller biotech on the map. It uses the same winning strategy as tirzepatide — activating two gut-hormone receptors at once — and its early trial produced fast, large weight loss. It is still investigational, and it comes in two flavors: an injection and a pill.
In plain terms: it's a tirzepatide-style "dual agonist" from a different company, and its first big trial dropped a lot of weight in a short time.
What it is
VK2735 is a GIP/GLP-1 receptor dual agonist developed by Viking Therapeutics1. "Dual agonist" means one molecule switches on two incretin receptors:
- GLP-1 receptor — the appetite-suppressing target semaglutide uses.
- GIP receptor — the second incretin receptor that tirzepatide added.
That is exactly tirzepatide's two-receptor recipe, and dual GIP/GLP-1 agonists are among the most effective weight-loss agents studied to date4. Viking is developing VK2735 in both a subcutaneous (injected) and an oral form — giving it a foot in each camp of the market.
The mechanism
Incretins are gut hormones released after meals that curb appetite and improve how the body handles glucose. Activating both the GIP and GLP-1 receptors together tends to produce more weight loss than hitting GLP-1 alone — the rationale that made tirzepatide a blockbuster and now drives a wave of GIP/GLP-1 and triple-agonist programs32. VK2735 is one of the most advanced of those challengers.
What the trials actually found
VK2735's headline is its phase-2 result, and it was striking for how *fast* it arrived:
| Study | Design | Key result | Year |
|---|---|---|---|
| Bays et al. — VENTURE1 | Phase 2, randomized, double-blind, placebo-controlled, 13 weeks (subcutaneous) | Dose-dependent weight loss of 9.1% (2.5 mg) to 14.7% (15 mg) vs 1.7% on placebo; 93% lost ≥5% | 2026 |
In the VENTURE study, adults with obesity or overweight (people with diabetes were excluded) received weekly subcutaneous VK2735 for just 13 weeks1. Mean weight loss ran from 9.2 kg (9.1%) at the lowest dose to 14.6 kg (14.7%) at the highest, against 1.8 kg (1.7%) on placebo. And it was broad, not just an average: 93% (130 of 140) of participants on active treatment lost at least 5% of their body weight1.
In plain terms: ~15% weight loss in about three months is a fast trajectory — the kind of early number that makes a drug a serious contender.
Why the numbers stand out
Context matters here. The big approved drugs reach their headline weight-loss figures over roughly a year of dosing. VENTURE hit ~15% in 13 weeks1 — a steeper early slope. Two honest caveats keep that in perspective: 13 weeks is a *short* trial, and the curve over a full year is what actually decides where VK2735 lands versus tirzepatide and the triple agonists4. Early speed is promising; it is not yet a finished comparison.
Side effects and safety
The safety profile is the expected class one. As a GIP/GLP-1 agonist, VK2735's most likely side effects are gastrointestinal — nausea, vomiting, diarrhea — typically dose-dependent and most common while the dose is being escalated, which is standard for the incretin class2. The honest caveats:
- It's phase-2-stage. VENTURE was short and mid-sized; rare and long-term risks aren't characterized yet, and that's what larger, longer trials are for.
- No diabetes data here. VENTURE excluded people with diabetes1, so its results speak to weight management in non-diabetic obesity, not to glycemic use.
Investigational status
To be plain: VK2735 is not an approved medicine. As of 2026 it is a Viking Therapeutics candidate with phase-2 data reported and larger trials ahead, in both subcutaneous and oral programs. Everything solid known about it comes from those trials. This page explains what it is and what the trial showed — not how to use it — and it takes no position on sourcing.
The short version
VK2735 is a GIP/GLP-1 receptor dual agonist from Viking Therapeutics — tirzepatide's two-receptor strategy in a new molecule, in both injectable and oral forms. In the phase-2 VENTURE study it produced fast, dose-dependent weight loss of roughly 9% to 15% in just 13 weeks, with 93% of treated participants losing ≥5%1. It is investigational, phase-2-stage, and unapproved — an educational overview only, not medical advice.